Organisation paid for research Program year 2025 Source: CMS Open Payments

University of Colorado Denver

Neither a doctor nor a teaching hospital

Research payments

$31,042,083

1,999 payments

Through program year 2025, University of Colorado Denver is reported as receiving $31,042,083 in research payments, across 1,999 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,959,693	214
2024	Research	$4,322,585	207
2023	Research	$4,549,152	188
2022	Research	$7,704,308	502
2021	Research	$3,726,894	286
2020	Research	$4,078,751	318
2019	Research	$4,700,700	284

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $6,660,485 24 payments
Dexcom, Inc. $4,859,127 79 payments
Pfizer Inc. $4,120,327 122 payments
Janssen Research & Development, LLC $2,250,339 139 payments
Gilead Sciences, Inc. $1,580,846 74 payments
Regeneron Pharmaceuticals, Inc. $1,018,968 73 payments
Medtronic MiniMed, Inc. $971,897 66 payments
W. L. Gore & Associates, Inc. $724,548 39 payments
Mallinckrodt Hospital Products Inc. $681,792 17 payments
Biogen, Inc. $610,714 5 payments

Studies the money was for Research payments · program years 2019–2025

A phase II study with safety run-in of ALX148 in combination with cetuximab and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer $5,238,060 2 payments
Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects $1,357,376 9 payments
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System - (G7 Pivotal) $1,091,459 7 payments
A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,022,840 37 payments
Targeting Immune Responses for Prevention of RA (TIP-RA) - University of Colarado $901,769 6 payments
Evaluation of the Safety and Effectiveness of the Dexcom Continious Glucose Monitoring (CGM) System (G7piv#2) $880,437 7 payments
Study of Efficacy Safety and Tolerability of Crisaborole and Pf07038124 With and Without Nbuvb in Nonsegmental Vitiligo A Phase 2A Randomized Double Blind Vehiclecontrolled Clinical Trial $666,789 2 payments
The Simple Study in Coronavirus, Severe Subjects $582,455 1 payment
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 $580,966 16 payments
CEP 304 670G Outcomes Study $546,695 31 payments

What the money was spent on Research payments · program years 2019–2025

Other $1,025 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.